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Abstract
Background:  Positron emission tomography (PET) imaging with fluorine-18 (18F)
Fluorodeoxyglucose (FDG) and flow tracer such as Rubidium-82 (82Rb) is an established method
for evaluating an ischemic but viable myocardium. However, the high cost of PET imaging restricts
its wider clinical use. Therefore, less expensive 18F FDG single photon emission computed
tomography (SPECT) imaging has been considered as an alternative to 18F FDG PET imaging. The
purpose of the work is to compare SPECT with PET in myocardial perfusion/viability imaging.
Methods: A nonuniform RH-2 thorax-heart phantom was used in the SPECT and PET acquisitions.
Three inserts, 3 cm, 2 cm and 1 cm in diameter, were placed in the left ventricular (LV) wall to
simulate infarcts. The phantom acquisition was performed sequentially with 7.4 MBq of 18F and 22.2
MBq of Technetium-99m (99mTc) in the SPECT study and with 7.4 MBq of 18F and 370 MBq of 82Rb
in the PET study. SPECT and PET data were processed using standard reconstruction software
provided by vendors. Circumferential profiles of the short-axis slices, the contrast and viability of
the inserts were used to evaluate the SPECT and PET images.
Results: The contrast for 3 cm, 2 cm and 1 cm inserts were for 18F PET data, 1.0 ± 0.01, 0.67 ±
0.02 and 0.25 ± 0.01, respectively. For 82Rb PET data, the corresponding contrast values were 0.61
± 0.02, 0.37 ± 0.02 and 0.19 ± 0.01, respectively. For 18F SPECT the contrast values were, 0.31 ±
0.03 and 0.20 ± 0.05 for 3 cm and 2 cm inserts, respectively. For 99mTc SPECT the contrast values
were, 0.63 ± 0.04 and 0.24 ± 0.05 for 3 cm and 2 cm inserts respectively. In SPECT, the 1 cm insert
was not detectable. In the SPECT study, all three inserts were falsely diagnosed as "viable", while
in the PET study, only the 1 cm insert was diagnosed falsely "viable".
Conclusion: For smaller defects the 99mTc/18F SPECT imaging cannot entirely replace the more
expensive  82Rb/18F PET for myocardial perfusion/viability imaging, due to poorer image spatial
resolution and poorer defect contrast.
Background
Fluorine-18 (18F) Fluorodeoxyglucose (FDG) single pho-
ton emission computed tomography (SPECT) imaging
has been considered as an alternative to 18F FDG positron
emission tomography (PET) imaging for evaluating
injured but viable myocardium [1,2]. SPECT 18F imaging
is sometimes performed as simultaneous Technetium-
99m sestamibi (99mTc MIBI)/18F FDG perfusion/viability
Published: 31 October 2006
BMC Nuclear Medicine 2006, 6:5 doi:10.1186/1471-2385-6-5
Received: 02 August 2006
Accepted: 31 October 2006
This article is available from: http://www.biomedcentral.com/1471-2385/6/5
© 2006 Knešaurek and Machac; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Nuclear Medicine 2006, 6:5 http://www.biomedcentral.com/1471-2385/6/5
Page 2 of 8
(page number not for citation purposes)
myocardial studies [3,4]. The main limitations of this
technique are poor resolution of the 18F and 99mTc SPECT
images and, when acquired simultaneously, degradation
of the 99mTc MIBI images due to 18F downscatter to the
99mTc window. The 18F images are also influenced by high
septal penetration and poor sensitivity, due to the limited
stopping power of the detector crystal in standard gamma
cameras [5]. In PET centres without a cyclotron, sequen-
tial Rubidium-82 (82Rb) and 18F FDG perfusion/viability
myocardial imaging are the most appropriate, because of
the availability of both isotopes [6-10]. 82Rb is a potas-
sium analog that, like Thalium-201, is extracted by living
cells. It is produced from a commercially available, FDA
approved strontium-82 generator, which must be replen-
ished 13 times a year. The short half-life of 82Rb allows
repeated acquisitions every 10 minutes. Neither, 18F FDG
or 82Rb require expensive on-site cyclotrons, as are needed
with  13N ammonia and 15O oxygen. Also, most health
care providers reimburse for 82Rb perfusion imaging, and
more recently for 18F FDG viability myocardial imaging.
The objective of our work was to compare 18F SPECT with
PET in myocardial perfusion/viability imaging in the clas-
sification of simulated myocardial defects for "viability"
according to commonly applied criteria.
Methods
A nonuniform RH-2 thorax-heart phantom (Kyoto Scien-
tific Speciment Co., LTD, Kyoto, Japan) (Fig. 1) was used
in SPECT and PET acquisitions. Three inserts, 3 cm, 2 cm
and 1 cm in diameter, were placed in the left ventricular
(LV) wall to simulate small transmural infarcts (Fig. 2).
SPECT acquisitions were performed on a dual headed sys-
tem (T22 gamma camera, SMV, Twinsburg, Ohio) with
ultra-high-energy (UHE) collimator. The energy resolu-
tion of the system at 140 keV is 9.8%, and at 511 keV is
7.8%. The thickness of the NaI(Tl) crystal is 0.9525 cm (3/
8"). A step-and-shoot mode was used for SPECT acquisi-
tions, with a 64 × 64 acquisition and processing frame
matrix size and zoom of 1.5. The time per frame was 40
sec. The 64 frames were acquired over 360°. The radius of
rotation for the phantom study was 21 cm, which is also
a typical radius for our clinical SPECT acquisitions. The
pixel size in the acquisition and reconstructed images was
6.08 mm. SPECT data were processed using standard
reconstruction software based on a filtered backprojection
method. A Butterworth filter of 5th order and cut-off fre-
quency of 0.25 cycles/pixel was used in the reconstruction
for all studies. Neither attenuation nor scatter correction
was performed.
The UHE parallel-hole collimator, used for the 18F SPECT
imaging, has hexagonal holes 3.4 mm in diameter and
65.0 mm in length, with a septal thickness of 3.0 mm. The
collimator cores are mounted in an all-lead frame
designed for 511 keV imaging. Planar resolution as a func-
tion of distance for the UHE collimator, measured in air
with a 99mTc point source was FWHM = 3.9 mm, 10.6 mm,
and 14.0 mm for 0 cm, 10 cm and 15 cm distance, respec-
tively. The same planar resolution measured with an 18F
point source gave FWHM = 5.3 mm, 13.9 mm, and 18.2
mm for 0 cm, 10 cm and 15 cm distance, respectively [11].
The standard deviation was less than 0.5 mm in all meas-
urements and was obtained from three measurements.
This shows that planar resolution for the UHE collimator
is better for 99mTc than for 18F. Septal penetration for the
UHE collimator is 6.5% and for the low-energy-high-res-
olution collimator is 0.50% [5]. The quoted septal pene-
RH-2 thorax-heart phantom Figure 1
RH-2 thorax-heart phantom. A) In a left ventricular wall 
three inserts, 1 cm, 2 cm and 3 cm in diameter were placed 
in the same short-axis plane. B) Cardiac phantom is placed in 
water. Left ventricular wall is connected by Teflon tubes to 
remote filling system. Teflon rod simulates spine and sawdust 
simulates lungs.
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tration values were calculated for only single septi. Actual
septal penetration in clinical situations may account for
30%–50% of detected events [3].
A GE ADVANCE (General Electric Medical Systems, Mil-
waukee, WI) PET system was used in 2D mode for PET
acquisitions. The system has 18 detector rings and 12,096
bismuth germanate (BGO) 4 × 8 × 30 mm crystals. In 2D
mode, the system uses a tungsten collimator 1 × 120 mm
in size. The axial field of view is 15.2 cm. It is covered by
35 image planes. The axial sampling interval is 4.25 mm.
The transaxial field of view is 55.0 cm. The coincidence
window width is 12.5 ns and energy window is 300–650
keV. All 2D PET acquisitions were performed in high sen-
sitivity (HS) mode. The resolution of our PET system was
measured using an 18F line source and for HS mode,
FWHM = 4.44 ± 0.04 mm in the tangential direction and
FWHM = 4.85 ± 0.08 mm in the radial direction. The PET
images were reconstructed using a filtered backprojection
reconstruction method and Hanning smoothing filter
with an 0.5 cycles/pixel cutoff. The matrix size was 128 ×
128 and the pixel size was 4.29 mm. Attenuation correc-
tion using an 8-min transmission scan was applied in the
PET studies. Also, Bergstrom [12] scatter correction, pro-
vided by the vendor, was applied.
All phantom acquisitions were single-isotope studies in
order to avoid down-scatter. The SPECT study was per-
formed with 7.4 MBq of 18F and 22.2 MBq of 99mTc and
the PET study with 7.4 MBq of 18F and 370 MBq of 82Rb.
These activities were injected into the phantom LV wall,
which with the three inserts had a volume of 140 ml. Con-
sequently, the radioactivity concentrations in the LV wall
were 52.9 kBq/ml for 18F, 158.6 kBq/ml for 99mTc and
2.64 MBq/ml for 82Rb.
Circumferential profiles of the short-axis slices (figs. 3 and
4), the contrast, and the defect severity of the inserts were
used to evaluate the SPECT and PET images. The contrast
value was calculated as a ratio C = (A-B)/(A+B), where A
and B are the average activities in region-of-interest (ROI)
covering the normal and cold areas, respectively. In the
SPECT study, 3 × 3 pixel (region-of-interest) ROIs cover-
ing 333 mm2 were used, and in the PET study 4 × 4 pixel
ROIs covering 294 mm2 were used. The different size ROIs
in SPECT and PET were used to approximately cover the
same area, although the PET ROI was slightly smaller. In
all studies, three adjacent short-axis slices were used, and
their average contrast value and standard deviation were
calculated.
Two criteria were used to determine "viability" or "nonvi-
ability" [13-24]. First, for each isotope images, i.e., 99mTc,
82Rb and 18F images, if the minimum value in the lesion
(MIN) was less than 50% of the maximum LV value
(MAX), the lesion was considered to be nonviable. In
addition to the above mentioned criterion for nonvaibil-
ity, in the SPECT study, the minimum lesion value in the
Short-axis slices Figure 3
Short-axis slices. Short-axis slices in the 99mTc/18F SPECT 
cardiac phantom study.
18F  SPECT
99mTc  SPECT
Position of inserts Figure 2
Position of inserts. The 3 cm insert was placed at 90 
degrees, 1 cm insert at 200 degrees and 2 cm insert at 270 
degrees.
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18F image (MIN(18F)) should be equal to or less than the
same corresponding minimum lesion value in the 99mTc
image (MIN(99mTc)). In the PET study, the minimum
lesion value in the 18F image should be equal to or less
than the same the minimum lesion value in the 82Rb
image (MIN(82Rb)). If the MIN(18F) is greater than the
same lesion MIN(99mTc) or MIN(82Rb), for SPECT or PET
study, respectively, then the lesion is considered viable
(mismatch pattern).
By definition, the inserts, not containing any activity, were
considered as a "nonviable" gold standard.
Results
Figures 3 and 4 show short axis slices from the 99mTc/18F
SPECT study and from the 82Rb/18F PET study, respec-
tively. In the SPECT study (Fig. 3) the 99mTc images have
better resolution and contrast than the corresponding 18F
images [5,11]. However, in the PET study (Fig. 4) the situ-
ation is the opposite, i.e. the 18F images have better reso-
lution and contrast compared with the corresponding
82Rb images. Comparing the SPECT with PET images (Fig.
3 and Fig. 4) one can see that PET images have much bet-
ter resolution and, except for the 99mTc 3 cm insert, the
contrast values are better than in the SPECT images,
regardless of the isotope used. For 18F PET data the con-
trast for 3 cm, 2 cm and 1 cm inserts was 1.0 ± 0.01, 0.67
± 0.02 and 0.25 ± 0.01, respectively. For 82Rb PET data the
corresponding contrast values were 0.61 ± 0.02, 0.37 ±
0.02, and 0.19 ± 0.01, respectively. For 18F SPECT the con-
trast values were, 0.31 ± 0.03 and 0.20 ± 0.05 for 3 cm and
2 cm inserts respectively. For 99mTc SPECT the contrast val-
ues were, 0.63 ± 0.04 and 0.24 ± 0.05 for 3 cm and 2 cm
inserts respectively. In the SPECT study the 1 cm insert was
not visually detectable (Fig. 3 and Fig. 5).
The total number of counts was 2.5 times higher in the
PET 18F study vs. the SPECT 18F study. The total number of
counts in the PET study was calculated as total prompt
counts minus total delays (randoms), and they include
scatter events.
Figures 5 and 6 show circumferential profiles from the
short-axis slices shown in fig. 3 and fig. 4, respectively,
normalized to 10,000 counts. Normalization provided
easier calculations of nonviability/viability of the insert
areas, using the criteria described above. Table 1 gives
minimum values in the insert areas as percentage of the
maximum, i.e. 10,000 values. Based on the criteria
described in the methods section, nonviability/viability
for the inserts were calculated and presented in Table 2.
Based on the 99mTc/18F dual-isotope criteria used
(Tables 1 and 2), SPECT failed, for all three inserts, to pro-
vide the correct result (nonviable), while the 82Rb/18F
PET study correctly identified the two larger nonviable
lesions. The region of the 1 cm insert was falsely diag-
nosed as viable by using the criteria described in the meth-
ods section, because MIN(18F) was 60% of the MAX(18F)
value in the LV wall. However, the 1 cm insert area is
clearly visible in 18F and R-82 PET images (Fig. 4) and
their corresponding circumferential profiles (Fig. 6). On
the contrary, in the 99mTc/18F SPECT study, the 1 cm
insert was not clearly visible in the reconstructed images
(Fig. 3) and circumferential profiles (Fig. 5).
Discussion
The results show that PET study provides images of better
resolution and sensitivity than SPECT study. This results
in better contrast for cold lesions created by the inserts
and better determination of viability/nonviability using
standard criteria. The differences in resolution and sensi-
tivity between PET and SPECT studies are significant. The
difference in sensitivity between the PET 18F study vs. the
SPECT 18F study is a factor of 2.5. The difference in resolu-
tion is less pronounced, but sill present. For 18F SPECT the
FWHM = 5.3 mm, while for 18F PET FWHM = 4.44 ± 0.04
mm in the tangential direction and FWHM = 4.85 ± 0.08
mm in the radial direction. These differences in resolution
and sensitivity results in significantly better PET images
comparing with the SPECT images in the study (Fig. 3, 4,
5, Fig. 6).
Using commonly applied criteria [13-24], SPECT failed
for all three inserts to provide the accurate diagnosis of
nonviability, which is significant drawback. While 1 cm
lesion may not be clinically important, as discussed
Short-axis slices Figure 4
Short-axis slices. Short-axis slices in the 82Rb/18F PET car-
diac phantom study.
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below, failure to properly classify 2 cm and 3 cm lesions
may be a problem for wider 18F SPECT clinical applica-
tion. On the other hand, PET correctly diagnosed 2 cm
and 3 cm lesions as nonviable and failed only for 1 cm
insert to provide accurate diagnosis because MIN(18F) was
60% of the MAX(18F) value in the LV wall. One way to
improve PET diagnostics accuracy is to raise the threshold
from 50% to 60% for our PET system. But, 1 cm lesion is
not of clinical importance because question of viability
usually apply to large segment or multisegment region.
However, in the PET study 1 cm insert was clearly visible
in both the 18F and 82Rb images, while in the 99mTc/18F
SPECT study a 1 cm insert was not clearly visible in the
images and circumferential profiles (Fig.3, 4, 5, Fig. 6).
In addition, an important difference between the SPECT
and PET images of the phantom was that 18F SPECT
images were of inferior quality compared with SPECT
99mTc images, while 18F PET images were better in quality
than corresponding 82Rb PET images. Consequently, for
SPECT, the defects were seen as mismatches, while in PET
they tended to be seen as reverse mismatches.
The reason for this is that the gamma camera was opti-
mized for 99mTc 140 keV photon imaging. Resolution
properties for 18F imaging are better on the PET system
than on the gamma camera. Septal penetration is also a
significant problem in gamma camera 18F imaging. In our
high count phantom studies sensitivity was not the main
issue, but in a clinical situation that can also be a problem
for standard gamma cameras. For a 0.9525 cm (3/8")
thick NaI(Tl) crystal 73% of 18F 511 keV photons do not
interact, 15% interact through Compton scatter and only
12% through the photoelectric effect, which is the mode
most desirable for good detection. This means that for 18F
511 keV photons, standard gamma cameras have very
poor sensitivity. Doubling the thickness of the NaI(Tl)
crystal to 1.905 cm (3/4") will increase the number of
photoelectric interactions to 26%, Compton scatter to
20%, and will decrease the number of noninteracting
photons to 54%. But, still this represents relatively poor
sensitivity, especially when compared with 99mTc 140 keV
photons interacting with a 0.9525 cm (3/8") thick NaI(Tl)
crystal: 88% photoelectric effect, 2% Compton scatter and
only 10 % no interaction.
82Rb PET images have poorer resolution and contrast
when compared with 18F images due to a higher 82Rb pos-
itron maximum energy of 3.35 MeV (emitted 83% of the
time) and 2.57 MeV (emitted 12% of the time). In com-
parison, 18F positron maximum energy is only 0.64 MeV.
Higher positron energy results in higher average distance
positron travel in medium prior to annihilation, 2.40 mm
for 82Rb vs. 0.35 mm for 18F.
Circumferential profiles Figure 5
Circumferential profiles. Circumferential profiles from short-axis slices shown in fig. 3.
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This study examined the effect of system resolution on the
classification of small intramural defects as "viable" or
"nonviable" by commonly used criteria [13-24]. Over the
last two decades, a variety of criteria have been used to
define viability, few of which are exactly the same. Never-
theless, the criteria used here are some of the most com-
monly used. Use of alternate criteria, i.e., 60% threshold
[22,23], or other arbitrary or empirical criteria would
result in similar, if not identical, conclusions. In practice,
questions of viability usually apply to large segmental and
multisegmental regions of dysfunction, hypoperfusion
and hypometabolism [13-24], since small perfusion
(function) defects have little impact on LV functional
properties. Small defects of 2 cm or less would not be con-
sidered clinically for questions of viability. However, per-
ceived false mismatches at the edges of defects several cm
in extent may result in misclassification of significant por-
tions of the myocardium as viable in SPECT studies, as
would modest defects of 2–4 cm. To a lesser extent, false
negatives of viability may occur in 82Rb/18F PET studies.
A similar phantom comparison between SPECT and a
dedicated PET system [1] concluded that by using an
appropriate threshold to define a defect, SPECT can accu-
rately measure defect size similarly to the manner of PET.
Also, the same group recently published the results of
their clinical comparison of SPECT with PET in the assess-
ment of myocardial viability [4], and concluded that
SPECT provided similar information to that of PET and
MRI. The phantom used was very similar to our phantom,
the PET system was the same and, as in our study, motion
and background effects were not taken onto account.
Table 2: Clinical diagnosis
1 cm insert 2 cm insert 3 cm insert
99mTc/18F SPECT VIABLE VIABLE VIABLE
82Rb/18F PET VIABLE NONVIABLE NONVIABLE
Circumferential profiles Figure 6
Circumferential profiles. Circumferential profiles from short-axis slices shown in fig. 4.
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Table 1: COMPARISON OF SPECT 99mTc/18F AND PET 82Rb/18F 
IN CARDIAC PHANTOM STUDY*
1 cm insert 2 cm insert 3 cm insert
18F SPECT 85% 66% 54%
99mTc SPECT 80% 62% 23%
18F PET 60% 20% 0%
82Rb PET 68% 50% 24%
* Percentage of maximum valuesBMC Nuclear Medicine 2006, 6:5 http://www.biomedcentral.com/1471-2385/6/5
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These studies recognize already mentioned advantages of
PET over SPECT, which has higher spatial resolution,
higher count sensitivity and routine use of attenuation
and scatter correction in PET, but not in SPECT. However,
the difference in the UHE collimator design and proper-
ties, the difference in the gamma camera crystal thickens,
our 0.9525 cm (3/8") vs. 1.6 cm (5/8") thick NaI(Tl) crys-
tal in these studies [1,4], a difference in acquisition (360
degree in our studies vs. 180 degree in these studies) and
a difference in evaluation of SPECT and PET data lead us
to a slightly different conclusion.
Conclusion
The results of this phantom study suggest that for smaller
defects, the 99mTc/18F SPECT imaging cannot entirely
replace the more expensive 82Rb/18F PET for myocardial
perfusion/viability imaging, due to poorer image spatial
resolution and poorer defect contrast.
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